GlobalRPh Renal Dosing Masterv6.6
GlobalRPh source record

Gabapentin immediate-release (Neurontin)

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug5 sources available - open source summaries, references and comparisons

Neurontin / gabapentin / gabapentin IR

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (3)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (5)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

3 additional source qualifications - review before use
Gabapentin formulations have different renal rules

Immediate-release gabapentin, GRALISE and HORIZANT are not interchangeable renal protocols. HORIZANT also has indication-specific schedules.

Before applying: Select the actual formulation and indication before using a dose or dialysis instruction.

Exact-30 boundary not resolved by RX table wording

The RX table prints greater-than-30 to 59 and greater-than-15 to 29 bands; dialysis supplements are paired to maintenance regimens.

Before applying: Confirm the exact boundary and matched supplement in the complete current product table; no automatic dose calculation is provided.

NEURONTIN: printed renal bands leave a boundary unclear

The RX table prints >30 to 59 and >15 to 29; exactly 30 is not clearly assigned. The hemodialysis supplement also belongs with a selected maintenance regimen.

Before applying: Verify the current table rather than silently rounding into a band. Do not select a supplement without its corresponding maintenance context.

Also check: Gabapentin formulations have different renal rules; Exact-30 boundary not resolved by RX table wording; NEURONTIN: printed renal bands leave a boundary unclear

Official source

NEURONTIN (gabapentin) immediate-release oral products

Product / population
Adults and patients >=12 years for the renal table; not HORIZANT or GRALISE.
Renal measure
Not specified; verify before use

The selected label literally prints >30-59 and >15-29. It does not separately resolve exactly 30; confirm a threshold-boundary regimen with the prescriber rather than silently rounding.

Selected baseline doses

Adult postherpetic neuralgia: 300 mg once on day 1, twice on day 2, three times on day 3; subsequently titrate toward 600 mg three times daily as needed. Epilepsy in patients >=12 years: start 300 mg three times daily; usual maintenance 300-600 mg three times daily.

Label renal table

Cockcroft-Gault CrCl in mL/min; total daily doses: >=60, 900-3600 mg in three doses; >30-59, 400-1400 mg in two doses; >15-29, 200-700 mg once daily; at 15, 100-300 mg once daily. Below 15, reduce proportionately to CrCl.

Hemodialysis

Use the renal maintenance schedule plus a supplement after each 4-hour HD session: for the five corresponding at-15 maintenance columns (100/125/150/200/300 mg), supplements are 125/150/200/250/350 mg. Do not treat these as interchangeable fixed supplements.

Source revision: | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee9ad9ed-6d9f-4ee1-9d7f-cfad438df388

Scope: Source-read local summary; source-specific recommendations are not automatically interchangeable. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 3 source difference / applicability notes

Preserved GlobalRPh source

Preserved original GlobalRPh source

Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Official product label

NEURONTIN (gabapentin) immediate-release oral products

Adults and patients >=12 years for the renal table; not HORIZANT or GRALISE.

Renal method: See source.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - Neurontin

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Immediate-release gabapentin; source renal table for age 12 years and older.

Renal method: CrCl by Cockcroft-Gault in stable renal function, mL/min.
Retrieved: 2026-09-07

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - Gabapentin (Neurontin)

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Immediate-release NEURONTIN; renal table for patients at least 12 years old. Not GRALISE or HORIZANT.

Renal method: Creatinine clearance (mL/min); Cockcroft-Gault with stable serum creatinine.
Retrieved: 2026-09-07

Read local renal resultOpen original reference
Handbook

Renal Drug Handbook, fifth edition

Historical 2019 reference; renal bands retain the book's own method labels.

Renal method: See source.
Retrieved: 2026-09-05

Read local renal result

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 3 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

source ambiguity

Exact-30 boundary not resolved by RX table wording

The RX table prints greater-than-30 to 59 and greater-than-15 to 29 bands; dialysis supplements are paired to maintenance regimens.

How to use this: Confirm the exact boundary and matched supplement in the complete current product table; no automatic dose calculation is provided.

GlobalRPh RX List - Neurontin

Source difference identified; final patient-specific adjudication required.

ambiguous source boundary

NEURONTIN: printed renal bands leave a boundary unclear

The RX table prints >30 to 59 and >15 to 29; exactly 30 is not clearly assigned. The hemodialysis supplement also belongs with a selected maintenance regimen.

How to use this: Verify the current table rather than silently rounding into a band. Do not select a supplement without its corresponding maintenance context.

GlobalRPh RX List - Gabapentin (Neurontin)Gabapentin - GRALISE

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeNEURONTIN (gabapentin) immediate-release oral productsGlobalRPh RX List - NeurontinGlobalRPh RX List - Gabapentin (Neurontin)Renal Drug Handbook, fifth edition
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

Immediate-release gabapentin only. Do not apply this table to Horizant or Gralise. Source summary and reproduced table use different boundary notation.

Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/gabapentin/

Usual Gabapentin Dosing (Adults)

Usual initial dose: 300 mg every 8 hours. Usual maintenance: 300 to 600 mg every 8 hours. Maximum 3600 mg/day.

GRPH-gabapentin-01 · Source section: Usual Gabapentin Dosing (Adults)Renal section finder

Gabapentin Renal Dosing

Source summary: CrCl >60 mL/min, usual dose; 30 to 59, 400 to 1400 mg/day in divided doses, usually twice daily; 15 to 29, 200 to 700 mg/day; <15, 100 to 300 mg/day with the lower end for CrCl <7.5.

Reproduced package-insert table for patients age >=12 with renal impairment or hemodialysis:

CrCl (mL/min)Total daily doseListed dose regimens
>=60900 to 3600 mg300, 400, 600, 800 or 1200 mg three times daily
>30 to 59400 to 1400 mg200, 300, 400, 500 or 700 mg twice daily
>15 to 29200 to 700 mg200, 300, 400, 500 or 700 mg once daily
15100 to 300 mg100, 125, 150, 200 or 300 mg once daily
Post-hemodialysis supplemental doseAs aligned with the above columns125, 150, 200, 250 or 350 mg

Below CrCl 15, reduce daily dose proportionately; at 7.5 mL/min use half the dose for 15 mL/min. Hemodialysis maintenance is based on estimated CrCl, plus the corresponding supplemental dose after each 4 hours of HD. Cockcroft-Gault can reasonably estimate clearance in stable renal function; outpatient measurement is difficult. Renally impaired patients <12 years have not been studied.

GRPH-gabapentin-02 · Source section: Gabapentin Renal DosingRenal section finder

Hemodialysis

The source separate summary says CrCl <15: 100 to 300 mg/day, plus 125 to 350 mg after each dialysis proportional to maintenance dose. Patients receiving >=300 mg/day can receive the 350 mg supplement; other patients should use the lower end. The source directs readers to the table above for updated package-insert information.

GRPH-gabapentin-03 · Source section: HemodialysisRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

NEURONTIN (gabapentin) immediate-release oral products

Open original reference

Open / share this exact local source

NIH/NLM DailyMed - U.S. prescribing information · Adults and patients >=12 years for the renal table; not HORIZANT or GRALISE.

Renal method: Not specified in this summary.
Source date:
Retrieved: 2026-09-05

Source-read local summary; source-specific recommendations are not automatically interchangeable.

Selected baseline doses

Adult postherpetic neuralgia: 300 mg once on day 1, twice on day 2, three times on day 3; subsequently titrate toward 600 mg three times daily as needed. Epilepsy in patients >=12 years: start 300 mg three times daily; usual maintenance 300-600 mg three times daily.

gabapentin:dm-ee9ad9ed-6d9f-4ee1-9d7f-cfad438df388-1 · Source locator: 2.1-2.2

Label renal table

Cockcroft-Gault CrCl in mL/min; total daily doses: >=60, 900-3600 mg in three doses; >30-59, 400-1400 mg in two doses; >15-29, 200-700 mg once daily; at 15, 100-300 mg once daily. Below 15, reduce proportionately to CrCl.

gabapentin:dm-ee9ad9ed-6d9f-4ee1-9d7f-cfad438df388-2 · Source locator: 2.3, Table 1

Hemodialysis

Use the renal maintenance schedule plus a supplement after each 4-hour HD session: for the five corresponding at-15 maintenance columns (100/125/150/200/300 mg), supplements are 125/150/200/250/350 mg. Do not treat these as interchangeable fixed supplements.

gabapentin:dm-ee9ad9ed-6d9f-4ee1-9d7f-cfad438df388-3 · Source locator: 2.3, Table 1 and footnotes

Source-specific limits

The selected label literally prints >30-59 and >15-29. It does not separately resolve exactly 30; confirm a threshold-boundary regimen with the prescriber rather than silently rounding.

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee9ad9ed-6d9f-4ee1-9d7f-cfad438df388
Retrieved
2026-09-05
Exact label title
NEURONTIN (gabapentin) immediate-release oral products
DailyMed Set ID
ee9ad9ed-6d9f-4ee1-9d7f-cfad438df388
Labeler
Parke-Davis Div of Pfizer Inc
DailyMed page updated
2022-07-12
FDA application
New Drug Application
U.S. product identity basis
Exact named product and route appear in the selected U.S. prescription label; current retail availability was not independently assessed.
Hash meaning
Locally authored source summary, not original SPL/XML/PDF bytes
Local summary SHA-256
b1ec3edfc2ebb7e160202e627c37679ca6108146aee4823c8cd9a12d0e824ee2
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - Neurontin

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Immediate-release gabapentin; source renal table for age 12 years and older.

Renal method: CrCl by Cockcroft-Gault in stable renal function, mL/min.
Source date: Revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Printed renal bandTotal daily doseSchedule
At least 60900-3,600 mg/dayThree divided doses
Greater than 30 to 59400-1,400 mg/dayTwo divided doses
Greater than 15 to 29200-700 mg/dayOnce daily
15100-300 mg/dayOnce daily

Below 15, reduce in proportion to CrCl. Hemodialysis requires renal-function-based maintenance plus a matched supplement after each four hours of dialysis; the specific five maintenance/supplement pairs must be selected from original Table 1 and are not collapsed into a free-standing supplement range here. The printed band wording leaves an exact-30 boundary ambiguity; no cutoff was guessed. Renal dosing below age 12 was not studied. Do not substitute extended-release regimens.

RDM33-rxlist-gabapentin-C1 · Source locator: Table 1 and footnotes a/b: renal function and hemodialysis.

Source-specific limits

Exact-30 printed boundary and matched dialysis supplement table require reference review.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/neurontin-drug/
Retrieved
2026-09-07
Renal-function method
CrCl by Cockcroft-Gault in stable renal function, mL/min.
Source date/version
Revision date not established in selected retrieval.
Hash meaning
SHA-256 of the local authored summary only; original HTML/PDF/SPL bytes are not bundled or hashed.
Local summary SHA-256
a24f0d37430035814a597321571838993111e7f00eeb71ec0b90133938a063ef
Rxlist

GlobalRPh RX List - Gabapentin (Neurontin)

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Immediate-release NEURONTIN; renal table for patients at least 12 years old. Not GRALISE or HORIZANT.

Renal method: Creatinine clearance (mL/min); Cockcroft-Gault with stable serum creatinine.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The immediate-release table lists total daily doses of 900-3600 mg in three doses at CrCl >=60; 400-1400 mg in two doses in its printed >30 to 59 band; 200-700 mg once daily in its printed >15 to 29 band; and 100-300 mg once daily at 15. Below 15, reduce the daily dose proportionally. The printed bands do not clearly assign every boundary, notably exactly 30; do not silently round into a regimen. Hemodialysis requires a maintenance regimen plus a supplement after each four-hour treatment; use the complete paired source table rather than selecting an unpaired supplement. Renal dosing below age 12 was not studied.

RDM39-rxlist-gabapentin-4a4e22f7eb-C1 · Source locator: Selected renal dosing, use in renal impairment, warnings and clinical pharmacology subsections; see named sections in summary.

Source-specific limits

Boundary ambiguity and dialysis pairing are retained explicitly. This is not the complete supplemental-dose table.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/neurontin-drug/
Retrieved
2026-09-07
Renal-function method
Creatinine clearance (mL/min); Cockcroft-Gault with stable serum creatinine.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
34225a6be99ecc7ad64e4c778b6b0febe47ca8273b39b464cdcbdb7b0476439b
Separate handbook layer

Renal Drug Handbook cross-check

Handbook

Renal Drug Handbook, fifth edition

Open / share this exact local source

UK Renal Pharmacy Group / Ashley and Dunleavy / CRC Press · Historical 2019 reference; renal bands retain the book's own method labels.

Renal method: Not specified in this summary.
Source date: Not established
Retrieved: 2026-09-05

Historical handbook facts locally summarized; not a current U.S. label or a modern CRRT protocol.

Historical renal bands

At GFR 30-60 and 15-30 mL/min the handbook advises starting low and titrating to response. Below 15 it lists 300 mg on alternate days or 100 mg nightly initially. For neuropathic pain or restless legs in moderate/severe impairment it separately suggests starting 100 mg daily; it advises no loading dose for neuropathic pain in renal patients.

gabapentin:rdh5-471-1 · Source locator: Renal impairment; Other information

Historical replacement-therapy protocol

For HD/high-flux treatment it describes a 300-400 mg load in previously untreated patients, then 200-300 mg after each HD session, titrated to tolerability. The neuropathic-pain no-load exception still applies. APD/CAPD follows the <15 band; continuous therapy follows the 15-30 band.

gabapentin:rdh5-471-2 · Source locator: Renal replacement; Other information

Source-specific limits

The handbook HD-only approach and the label maintenance-plus-supplement approach are distinct. Do not add their doses together. The book's general gabapentin recommendations do not establish dosing for GRALISE or the enacarbil prodrug.

Source identity and provenance
Retrieved
2026-09-05
Handbook page
Printed page 471; PDF page 490
Hash meaning
Locally authored source summary, not original SPL/XML/PDF bytes
Local summary SHA-256
ac66ac0bd02a14a2d0578cd85c97a9339d4f3e2c67d8836edb98ed9fb680f2db

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 2 RX List, 0 professional, 1 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/gabapentin/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
400dba1ba2ea2e1089189d96a95ad34472320ab2c2252e924f46ab72185727a0
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report